Retavase, Rapilysin (reteplase) is an enzyme pharmaceutical. Reteplase was first approved as Retavase on 1996-08-29. It is used to treat myocardial infarction and ventricular dysfunction in the USA. It has been approved in Europe to treat myocardial infarction.
|Indication||myocardial infarction, ventricular dysfunction|
|Drug Class||Enzymes: tissue-type plasminogen activators|